A recent article by Applied Clinical Trials references a widely-held statistic that as few as 5% of eligible patients have participated in a clinical trial related to their disease. While some within the pharmaceutical industry debate the validity of this figure, all agree the low level of participation is concerning for all clinical research stakeholders.